A system being rebuilt around private providers
Vision 2030 aims to raise the private sector's share of healthcare delivery from 40% to 65% by 2030, with privatisation plans covering about 290 hospitals and 2,300 primary health centres [1]. Total healthcare spending is forecast at $76 billion in 2026, and private medical insurance premiums nearly doubled between 2018 and 2023, from $5.4 billion to $10.4 billion [1].
Listed healthcare valuations also give sellers a reference point. Healthcare listings raised $508 million across the Gulf in 2025, including SMC Hospitals on the Main Market and Basma Adeem and Wajd Life on Nomu [2].
Who pays, and on what terms
A clinic's revenue can look the same whether it comes from insurers, government referrals or patients paying themselves. The risks are not the same. We split revenue by payer, look at claims rejection rates and payment times, and test with insurers and referrers how the target is rated and whether its contracts are likely to renew on the same terms.
Clinicians, not just beds
In many clinic groups a small number of consultants drive a large share of revenue. If they leave, patients often follow. We look at revenue by clinician, tenure, and what keeps key people.
Staffing costs are also moving. The second phase of dental Saudisation took effect on 27 January 2026, raising the quota to 55% across nine dental specialties [3]. Plans written before then may understate what it costs to staff a new site.
Pharmaceuticals and medical supplies
For distributors and manufacturers, government tenders and local content rules shape the plan. Certain pharmaceutical products registered with the SFDA can receive an additional price preference of up to 20% in government purchasing, on top of the standard 10% [4]. We check which of the target's products qualify and whether it is winning the tenders the plan depends on.
What we test
| Question | How we test it |
|---|---|
| Who pays, and how reliably? | Payer mix, claims rejection, insurer interviews |
| Is there demand in the catchment? | Population, competing facilities, referral patterns |
| Can it recruit and keep clinicians? | Revenue by clinician, staff and recruiter interviews |
| Will new sites open on time and fill? | Licensing steps, payer contracts, staffing plans |
Questions we're asked
Do you speak to patients?
Rarely, and only with care. We usually learn more from referrers, insurers, corporate clients and staff.
Do you cover medical devices?
Yes, including distributors, where agency agreements and tender wins drive the plan.
Sources
- L.E.K. Consulting, From reimbursement to provision: Saudi Arabia's vertical integration window for health insurers, July 2026
- Fast Company Middle East, Saudi Arabia leads Gulf IPO market with 13 listings worth $3.7 billion
- Clyde & Co, The first Saudisation updates of 2026, February 2026
- Argaam, LCGPA unveils additional price preference mechanism for pharma sector, February 2025
